Clinical Trial Update: A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis [Phase 1]

View source ↗

Summary

Phase 1 trial evaluated AZD5634 for effects on mucociliary clearance, safety, tolerability, and pharmacokinetics in patients with cystic fibrosis. The study sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• AZD5634

Snippet

Sponsor: AstraZeneca | Conditions: Pulmonary/Respiratory Diseases | Phase 1 | Status: COMPLETED